{
    "2018-02-26": [
        [
            {
                "time": "",
                "original_text": "领先大市-A评级]医药行业每周观点：关注业绩超预期及估值增速具备高性价比的投资机会 首推葵花药业和济川药业",
                "features": {
                    "keywords": [
                        "医药行业",
                        "业绩超预期",
                        "估值增速",
                        "高性价比",
                        "葵花药业",
                        "济川药业"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：医药分销板块有望迎来戴维斯双击",
                "features": {
                    "keywords": [
                        "医药生物",
                        "分销板块",
                        "戴维斯双击"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}